Effects of nesiritide and dobutamine on heart rate variability in patients with decompensated heart failure
Doron Aronson(Technion – Israel Institute of Technology), Andrew J. Burger(Beth Israel Deaconess Medical Center), Darlene P. Horton(Scion)
Cited by 1
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
|American Heart Journal|2002|323
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
|Journal of the American College of Cardiology|1999|323
Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure
|Journal of the American College of Cardiology|2002|232